drugset / Trial / NCT00429559
Topotecan in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Carcinoma
Phase 1/2
Completed
31 enrolled
Hellenic Oncology Research Group
University Hospital of Crete · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Topotecan and gemcitabine are drugs globally registered for recurrent ovarian carcinoma. This trial will determine the maximum tolerated dose and the efficacy of this combination administered weekly in patients with platinum -resistant ovarian cancer.
Timeline
- Start
- 2006-06
- Primary completion
- 2011-07
- Completion
- 2011-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | 700 mg/m2 | Intravenous |
| Subject | Topotecan | Small molecule | 1.75 mg/m2 | Intravenous |